Odyssey Therapeutics Reports Q3 2026 Net Loss of $53.1 Million

What happened

Odyssey Therapeutics reported a third-quarter 2026 net loss of $53.1 million, up from $35.5 million a year earlier. Research and development spending rose to $42.1 million from $26.3 million. It had $387 million in cash and marketable securities at September 30, which it expects to fund operations into the second half of 2028.

Confirmed

Global impact / market context

The larger loss and higher research spending show that advancing Odyssey’s drug programs is consuming more cash than a year ago. Its stated runway into the second half of 2028 provides time for planned trials, but continued spending without sufficient future funding or revenue could shorten that period.

Analyst inference

The article reports clinical findings for OD-001 and plans to start a Phase 1/2a trial of OD-002 in the first half of 2027. These milestones could inform views of the company’s research progress, while trial execution and rising research costs remain relevant to its cash needs.

Analyst inference

What to watch

1. Track whether research and development spending continues to rise, since faster cash use could bring forward the point when Odyssey needs additional funding. Analyst inference
2. Watch for the planned start of the OD-002 Phase 1/2a trial in the first half of 2027 and healthy-participant data expected in the second half. Confirmed
3. Follow further OD-001 ulcerative-colitis analyses and evidence from patient cohorts, as clearer results could shape expectations for the drug program’s development. Analyst inference

Evidence

• Original source link unavailable